NCT00387920 - Sunitinib in Treating Young Patients With Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

September 30, 2012

Conditions

Central Nervous System MetastasesChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Embryonal TumorChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorRecurrent Childhood Central Nervous System Embryonal TumorUnspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG

sunitinib malate

Given orally

OTHER

pharmacological study

Correlative studies

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

Undergo DCE-MRI

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (17)

10032

Columbia University Medical Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

35294

University of Alabama at Birmingham, Birmingham

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48109

C S Mott Children's Hospital, Ann Arbor

63110

Washington University School of Medicine, St Louis

75390

University of Texas Southwestern Medical Center, Dallas

77030

Baylor College of Medicine, Houston

94115

UCSF-Mount Zion, San Francisco

94143

University of California San Francisco Medical Center-Parnassus, San Francisco

98105

Seattle Children's Hospital, Seattle

92868-3874

Childrens Hospital of Orange County, Orange

02115

Dana-Farber Cancer Institute, Boston

M5G 1X8

Hospital for Sick Children, Toronto

H3T 1C5

Centre Hospitalier Universitaire Sainte-Justine, Montreal

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH